Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.